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ABSTRACT 
Background and purpose.  Rescue of F508del-cystic fibrosis transmembrane conductance 
regulator (CFTR), the most common cystic fibrosis (CF) mutation, requires small molecules 
that overcome protein processing, stability and channel gating defects.  Here, we investigate 
F508del-CFTR rescue by CFFT-004 (from WO2010/068863), a small molecule designed to 
independently correct protein processing and channel gating defects. 
Experimental approach.  Using CFTR-expressing recombinant cells and CF patient-derived 
bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating 
and stability with the patch-clamp and Ussing chamber techniques. 
Key results.  Chronic treatment with CFFT-004 improved modestly F508del-CFTR 
processing, but not its plasma membrane stability.  By contrast, CFFT-004 rescued F508del-
CFTR channel gating better than C18, an analogue of the clinically-used CFTR corrector 
lumacaftor.  Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR 
channel gating.  However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with 
a comparable mechanism of CFTR dysfunction as F508del-CFTR.  To investigate the 
mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations.  Potentiation 
by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the 
revertant mutation G550E.  These data suggest that correction, but not potentiation by CFFT-
004 might involve nucleotide-binding domain 1 of CFTR. 
Conclusions and implications.  CFFT-004 is a dual-acting small molecule with independent 
corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells 
and native airway epithelia.  The limited efficacy and potency of CFFT-004 suggests that 
combinations of small molecules targeting different defects in F508del-CFTR might be a more 
effective therapeutic strategy than a single agent. 
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INTRODUCTION 
 The genetic disease cystic fibrosis is caused by mutations in the ATP-binding cassette 
(ABC) transporter cystic fibrosis transmembrane conductance regulator (CFTR), an epithelial 
Cl- channel with complex regulation (Riordan et al., 1989; Gadsby et al., 2006; Ratjen et al., 
2015) (channel nomenclature follows Alexander et al., 2015).  The molecular basis of most 
cases of CF is protein misfolding caused by the F508del mutation (Cheng et al., 1990).  
Misfolded F508del-CFTR is recognized by the endoplasmic reticulum (ER) quality control 
system, ubiquitinated and destroyed by the proteasome (for review, see Lukacs & Verkman, 
2012; Farinha et al., 2013b).  Any F508del-CFTR protein that escapes ER quality control and 
reaches the plasma membrane exhibits two further defects: plasma membrane instability 
(Lukacs et al., 1993) and defective channel gating (Dalemans et al., 1991).  Thus, F508del-
CFTR disrupts profoundly CFTR function, leading to transepithelial fluid and electrolyte 
abnormalities (Frizzell & Hanrahan, 2012) and hence, organ dysfunction (Ratjen et al., 2015). 
 
 In the search for drugs to rescue the plasma membrane function of CFTR, two classes 
of small molecules have been identified.  First, CFTR correctors, which traffic mutant proteins 
to the plasma membrane (Lukacs & Verkman, 2012).  Second, CFTR potentiators that enhance 
greatly mutant channel gating (Cai et al., 2011).  When tested alone, neither CFTR correctors 
(e.g. lumacaftor; VX-809; Van Goor et al., 2011) nor CFTR potentiators (e.g. ivacaftor; VX-
770; Van Goor et al., 2009) had clinical benefit for CF patients with the F508del mutation 
(Clancy et al., 2012; Flume et al., 2012).  By contrast, chronic co-administration of lumacaftor 
and ivacaftor to CF patients homozygous for the F508del mutation increased modestly lung 
function, but improved markedly disease stability (Wainwright et al., 2015), leading to the 
approval of lumacaftor-ivacaftor combination therapy. 
 
 An attractive alternative approach to combination therapy for F508del-CFTR would be 
the use of a single small molecule that corrects both the protein processing and channel gating 
defects of F508del-CFTR.  These dual-acting small molecules are termed CFTR corrector-
potentiators (Kalid et al., 2010).  Interestingly, the first CFTR corrector-potentiator, the 
pyrazole VRT-532 (Van Goor et al., 2006), was identified serendipitously (Wang et al., 2006).  
Previous work suggests that there are at least two types of CFTR corrector-potentiators.  Some 
dual-acting small molecules promote F508del-CFTR deliver to the plasma membrane, but do 
not potentiate robustly channel gating when added acutely.  Instead, these agents, which include 
lumacaftor and its analogue C18 (VRT-534) enhance channel activation by cAMP-dependent 
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phosphorylation (Eckford et al., 2014).  Other dual-acting small molecules (e.g. 
cyanoquinolines; Phuan et al., 2011) independently correct the F508del-CFTR trafficking 
defect and acutely potentiate channel gating.  The mechanism of action of this latter class of 
compounds is not well understood. 
 
 Here, we investigated the mechanism of action of the dual-acting small molecule CFFT-
004 (from WO2010/068863), synthesized by EPIX Pharmaceuticals Inc., a CFTR corrector-
potentiator with independent F508del-CFTR corrector and potentiator activities.  With the 
Ussing chamber and patch-clamp techniques, we analysed the impact of correction and 
potentiation with CFFT-004 on the plasma membrane stability and channel gating defects of 
F508del-CFTR.  To probe the mechanism of action of CFFT-004, we used the F508del-CFTR 
revertant mutations G550E and R1070W (deCarvalho et al., 2002; Thibodeau et al., 2010) and 
to explore specificity, we studied A561E, another class II-III-VI CF mutation (Veit et al., 2016) 
with closely comparable defects as F508del-CFTR (Mendes et al., 2003; Wang et al., 2014).  
Our results demonstrate that CFFT-004 has differential effects on F508del-CFTR, but fails to 
rescue A561E-CFTR.  It rescues F508del-CFTR channel gating better than it improves protein 
processing, but is without effect on channel stability. 
 
METHODS 
Cells and cell culture 
 For biochemical and functional studies of recombinant CFTR, we used baby hamster 
kidney (BHK) cells stably expressing wild-type human CFTR, the CF mutants F508del and 
A561E and the revertant mutations G550E, R1070W and G550E-R1070W (Roxo-Rosa et al., 
2006; Farinha et al., 2013a); mouse mammary epithelial (C127) cells stably expressing wild-
type human CFTR (Marshall et al., 1994), Fischer rat thyroid (FRT) epithelial cells stably 
expressing F508del human CFTR (Figure 1, 1F12, M470 cell line; Bridges et al., 2013; Figure 
5, Hughes et al., 2008) and Chinese hamster ovary (CHO) cells stably expressing F508del 
murine CFTR.  Cells were generous gifts of CR O’Riordan (Genzyme; C127 cells), RJ Bridges 
(Rosalind Franklin University of Medicine and Science; FRT cells), LJV Galietta (Instituto 
Giannina Gaslini; FRT cells) and BJ Wainwright (University of Queensland; CHO cells).  Cells 
were cultured and used as described previously (Sheppard & Robinson, 1997; Lansdell et al., 
1998; Zegarra-Moran et al., 2002; Hughes et al., 2008; Schmidt et al., 2008) with the exceptions 
that (i) FRT cells used for Figure 1 were seeded on Snapwell filter inserts (cat. no. 3801, 
Corning, NY, USA) and grown for at least 7 days before use and (ii) the selection agent for 
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F508del murine CFTR expressing CHO cells was methotrexate (AAH Pharmaceuticals Ltd., 
Coventry, UK).  For functional studies of native CFTR, we used primary cultures of human 
bronchial epithelial (hBE) cells homozygous for F508del- or A561E-CFTR.  hBE cells were 
either expanded from frozen stock generously supplied by SH Randell (University of North 
Carolina) and differentiated at an air-liquid interface (ALI) (Neuberger et al., 2011) or isolated, 
cultured and ALI differentiated as described previously (Awatade et al., 2015).  To promote the 
plasma membrane expression of F508del- and A561E-CFTR, cells were incubated at 26 – 27 
°C for 24-72 h or treated with small molecules for 24 h at 37 °C prior to use (Denning et al., 
1992; Mendes et al., 2003; Van Goor et al., 2011; Meng et al., 2017).  When testing the effects 
of chronic drug treatments on F508del- and A561E-CFTR, the fetal bovine serum concentration 
of media was reduced to 1% (v v-1).  In patch-clamp experiments, to remove drugs from the 
extracellular solution small molecule-treated cells were thoroughly washed with drug-free 
physiological solutions before experiments were commenced.  However, the maximum period 
these cells were left in drug-free solution before study did not exceed 30 minutes.  The single-
channel behaviour of wild-type human CFTR in excised inside-out membrane patches from 
different mammalian cells is equivalent (Chen et al., 2009). 
 
Western blotting 
 To assess the effects of small molecules on the expression of CFTR protein, we used 
Western blotting (Farinha et al., 2002).  We lysed cells, loaded SDS-polyacrylamide mini-gels 
(7% (w v-1) polyacrylamide; BioRad, Hercules, CA, USA) with 30 mg total protein (5 mg for 
wild-type CFTR) and separated protein electrophoretically.  After transfer of proteins to 
Immobilon-P PVDF membranes (Merck KGaA, Darmstadt, Germany), we probed membranes 
with the mouse anti-CFTR monoclonal antibody 596, which recognizes nucleotide-binding 
domain 2 (NBD2; residues 1204 – 1211) (Cui et al., 2007) diluted at 1:1,000 using a secondary 
anti-mouse peroxidase-labelled monoclonal antibody at 1:3,000 (cat. no. 170-6516; BioRad).  
Western blots were developed using the Clarity Western ECL detection system (Pierce, 
Rockford, IL, USA). 
 
Ussing chamber studies of recombinant CFTR to determine CFFT-004 concentration-
response relationships 
 We recorded F508del-CFTR-mediated transepithelial Cl- currents in FRT epithelia 
using a large Cl- concentration gradient to magnify current size without permeabilising the 
basolateral membrane (Kalid et al., 2010).  FRT epithelia were mounted in Ussing chambers 
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(model P2300; Physiologic Instruments Inc., San Diego, CA, USA).  The solution bathing the 
basolateral membrane contained (mM): 137 NaCl, 4 KCl, 1.8 CaCl2, 1.0 MgCl2, 10 HEPES, 10 
glucose adjusted to pH 7.4 with NaOH.  The solution bathing the apical membrane was identical 
to that of the basolateral solution with the exception that Cl- was replaced by gluconate to create 
a transepithelial Cl- concentration gradient (basolateral [Cl-], 144.6 mM; apical [Cl-], 9.6 mM).  
All solutions were maintained at 37 °C and bubbled continuously with air under low pressure 
to drive buffer circulation for improved compound mixing. 
 
 To record short-circuit current (Isc), we used a Physiologic Instruments VCC MC8 
multichannel voltage/current clamp.  After cancelling voltage offsets, transepithelial voltage 
was clamped at 0 mV and Isc recorded every 20 s at 37 °C with transepithelial resistance 
monitored in parallel using ±5 mV voltage steps of 620 ms duration.  After recording baseline 
Isc for ~10 minutes, we added the cAMP agonist forskolin (10 M), the CFTR potentiator 
genistein (20 M) and the CFTR inhibitor CFTRinh-172 (20 M) sequentially and cumulatively 
at 10 – 20 minute intervals.  All compounds were added as 500x or 1000x stock solutions to 5 
ml physiological salt solutions bathing the apical and basolateral membranes.  For acute 
additions of CFFT-004, 1000x stock solutions in DMSO were added to the apical solution only.  
The resistance of the filter and solutions, in the absence of cells, was subtracted from all 
measurements.  Under the experimental conditions that we used, flow of current from the 
basolateral to the apical solution corresponds to Cl- movement through open CFTR Cl- channels 
and is shown as an upward deflection. 
 
 We consider the CFTRinh-172-sensitive Isc after the addition of forskolin and genistein 
a measure of F508del-CFTR correction using the relationship: 
 
   ICFTR = N·i·Po,     (Eq. 1) 
 
where, ICFTR is the CFTR-mediated transepithelial Cl- current, N, the total number of CFTR Cl- 
channels in the apical membrane, i, the current flowing through a single open CFTR Cl- channel 
and Po, its open probability.  For the CFTRinh-172-sensitive current to be a valid measure of 
F508del-CFTR correction, it is necessary to assume that after the addition of forskolin and 
genistein in the above protocol, F508del-CFTR Cl- channels possess the same Po regardless of 
the small molecule used for correction.  In this case, ICFTR is then directly proportional to the 
total number of F508del-CFTR Cl- channels in the apical membrane (N).  Although we have 
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no proof for this assumption, we consistently find that the increase in Isc achieved with genistein 
(20 M) varies dependent upon how much CFTR-mediated transepithelial Cl- current is 
stimulated prior to genistein addition.  In contrast to measurements at 37 °C (Figure 1), 
forskolin-stimulated CFTR Cl- currents recorded at 27 °C reach a steady plateau.  Under these 
experimental conditions, the genistein response varies from ~40% of the total CFTRinh-172-
sensitive Isc using a pure CFTR corrector (e.g. corr-4a; Pedemonte et al., 2005) to virtually 
nothing or even a negative response using a pure CFTR potentiator or a dual-acting small 
molecule prior to genistein addition. 
 
 To determine half-maximal concentrations (EC50 values) for CFFT-004 correction, 
potentiation and dual-action (correction-potentiation), we constructed CFFT-004 
concentration-response relationships using Isc measurements acquired from F508del-CFTR-
expressing FRT epithelia.  The EC50 values for correction and dual-action were determined 24 
h post compound treatment from the CFTRinh-172-sensitive and peak forskolin Isc values, 
respectively.  Concentration-response data were fitted using the following formula: 
 
   Isc = A + B*(cmpdH/(cmpdH+EC50H)) (Eq. 2) 
 
where A and B represent the fit parameters at zero and saturating concentrations of compound 
(cmpd) with the Hill coefficient (H) set to 1. 
 
 To obtain EC50 values for CFFT-004 potentiation, we used Eq. 2 (Hill coefficient set to 
1) to fit the maximum Isc responses elicited by additions of increasing concentrations of CFFT-
004 to the solution bathing the apical membrane of F508del-CFTR-expressing FRT epithelia.  
To account for differing amounts of forskolin-stimulated CFTR Cl- current between F508del-
CFTR-expressing FRT epithelia and the deactivation of CFTR-mediated Cl- currents prior to 
CFFT-004 addition, we determined slope and Isc values for each Isc recording at the time of 
CFFT-004 addition and normalized the slope-corrected, maximal CFFT-004 response to Isc 
values obtained prior to compound addition. 
 
Ussing chamber studies to evaluate the plasma membrane stability of recombinant CFTR 
 Ussing chamber studies to evaluate the effects of small molecules on the plasma 
membrane stability of F508del-CFTR were performed as described by Hughes et al. (2008) and 
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Meng et al. (2017).  Following 24 h correction with either CFFT-004 or C18, F508del-CFTR-
expressing FRT epithelia were treated with cycloheximide (50 g ml-1) 15 minutes prior to t = 
0 h.  At t = 0, 2, 4 and 6 h after cycloheximide treatment, FRT epithelia were mounted in Ussing 
chambers and the Isc responses to forskolin, ivacaftor and CFTRinh-172 recorded. 
 
 CFTR-mediated transepithelial Cl- currents were recorded using a large Cl- 
concentration gradient without permeabilizing the basolateral membrane.  The solution bathing 
the basolateral membrane contained (mM): 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3 
CaCl2, 0.5 MgCl2, 10 HEPES and 4.2 NaHCO3, adjusted to pH 7.2 with Tris ([Cl-], 149 mM).  
The solution bathing the apical membrane was identical to that of the basolateral solution with 
the exception that (mM): 133.3 Na gluconate + 2.5 NaCl and 5 K gluconate replaced 140 NaCl 
and 5 KCl, respectively, ([Cl-], 14.8 mM).  For the purpose of illustration, unless otherwise 
indicated, in stability experiments Isc time courses are displayed as Isc with the Isc value 
immediately preceding forskolin addition designated as 0 A cm-2; file sizes were compressed 
by 100-fold data reduction.  To determine transepithelial resistance (Rt), brief voltage pulses 
(amplitude 10 mV; frequency 0.1 Hz) were applied to epithelia to generate brief current 
deflection; Rt was then calculated using Ohm’s law. 
 
Short-circuit and equivalent current studies of CF human bronchial epithelia 
 After two passages in BEGMTM Bronchial Epithelial Cell Growth Media (cat. no. CC-
3170, Lonza, USA), P3 hBE cells homozygous for F508del-CFTR were seeded at a density of 
5 x 105 cells cm-2 (170,000 cells/filter) on HTS Transwell 24-well filter inserts (cat no. 3378, 
Corning, NY, USA).  Cells were differentiated at an ALI as described by Neuberger et al. 
(2011) with the basolateral media changed every other day.  After 4-5 weeks of ALI culture, 
hBE cells typically formed electrically tight epithelia with a Rt of 200 – 600 Ω cm2 and were 
then used for equivalent current (Ieq) studies. 
 
 For F508del-CFTR potentiation studies, Ussing chamber recordings were performed on 
lumacaftor-rescued epithelia of differentiated hBE cells as described above for FRT epithelia.  
For F508del-CFTR correction studies, epithelia of differentiated hBE cells were treated from 
the basolateral side with either control (vehicle) or test compound and maintained at 37 °C and 
5% CO2.  After 24 h, the media bathing the basolateral membrane was removed and replaced 
with fresh HEPES-buffered (pH 7.4), compound- and bicarbonate-free F-12 culture media 
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(assay buffer).  Epithelia of differentiated hBE cells were immediately mounted onto the assay 
platform and equilibrated to ~37 °C for 30 min.  Transepithelial voltage (Vt) and Rt were 
monitored at ~6 min intervals using a 24-channel transepithelial current clamp amplifier 
(TECC-24, EP Design, Bertem, Belgium).  Ieq was calculated from values of Vt and Rt using 
Ohm’s law after correcting for series resistance and voltage offsets unrelated to Vt.  In the 
recorded Ieq, the first and second 4 data points reflect baseline currents under conditions where 
the epithelial Na+ channel (ENaC) is active (pre-benzamil addition) and inhibited (post-
benzamil; 6 M).  Six measurements were then made to determine Ieq after the sequential acute 
addition of forskolin (10 M), CFFT-004 (10 M) and the CFTR inhibitor CFTRinh-172 (20 
M).  Small molecules were pre-diluted to 10-fold concentrations in HEPES-buffered culture 
media and added to either the basolateral (forskolin) or apical (benzamil, forskolin, CFTR-004 
/ ivacaftor, genistein and CFTRinh-172) sides of the membrane.  In Ieq studies, CFTR-mediated 
changes in Ieq were used as a measure of functional CFTR surface expression or small molecule-
mediated functional rescue of mutant CFTR. 
 
Patch-clamp experiments 
 CFTR Cl- channels were recorded in excised inside-out membrane patches using an 
Axopatch 200A patch-clamp amplifier and pCLAMP software (both from Molecular Devices, 
Union City, CA) (Sheppard & Robinson, 1997).  The pipette (extracellular) solution contained 
(mM): 140 N-methyl-D-glucamine (NMDG), 140 aspartic acid, 5 CaCl2, 2 MgSO4 and 10 N-
tris[Hydroxymethyl]methyl-2-aminoethanesulphonic acid (TES), adjusted to pH 7.3 with Tris 
([Cl-], 10 mM).  The bath (intracellular) solution contained (mM): 140 NMDG, 3 MgCl2, 1 
CsEGTA and 10 TES, adjusted to pH 7.3 with HCl ([Cl-], 147 mM; free [Ca2+], < 10-8 M) and 
was maintained at 37 ºC using a temperature-controlled microscope stage (Brook Industries, 
Lake Villa, IL, USA) unless otherwise indicated. 
 
 After excision of inside-out membrane patches, we added the catalytic subunit of protein 
kinase A (PKA; 75 nM) and ATP (1 mM) to the intracellular solution within 5 minutes of patch 
excision to activate CFTR Cl- channels.  To minimise channel rundown, we added PKA to all 
intracellular solutions, maintained the ATP concentration at 1 mM and clamped voltage at –50 
mV.  The action of small molecules as CFTR potentiators was tested by addition to the 
intracellular solution in the continuous presence of ATP (1 mM) and PKA (75 nM).  Because 
of the rundown of F508del- and A561E-CFTR Cl- channels in excised membrane patches at 37 
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ºC (Wang et al., 2014), test interventions were not bracketed by control periods.  Instead, 
specific interventions with test small molecules were compared with the pre-intervention 
control period made with the same concentration of ATP and PKA, but without the test small 
molecule. 
 
 To investigate the effects of small molecules on the plasma membrane stability of 
F508del-CFTR, we monitored the thermal stability of F508del-CFTR in excised inside-out 
membrane patches (Wang et al., 2014).  Membrane patches were excised at 27 ºC and F508del-
CFTR Cl- channels activated by the addition of PKA and ATP to the intracellular solution.  
Once channels were fully activated and, potentiated when using CFTR potentiators, the 
temperature of the intracellular solution was increased to 37 ºC, which took 2 – 3 minutes.  To 
evaluate the thermal stability of F508del-CFTR at 37 ºC, we calculated Po and normalized Po 
values in 30 s intervals over a 9-minute period (Wang et al., 2014). 
 
 In this study, we used membrane patches containing ≤ 4 active channels (wild-type 
CFTR, number of active channels (N) = 1; F508del-CFTR, N ≤ 4; A561E-CFTR, N ≤ 4; 
F508del-G550E-CFTR, N ≤ 4; F508del-R1070W-CFTR, N ≤ 2; and F508del-G550E-R1070W-
CFTR, N ≤ 4).  To determine channel number, we used the maximum number of simultaneous 
channel openings observed during the course of an experiment (Cai et al., 2006).  To minimise 
errors, we used experimental conditions that robustly potentiate channel activity and verified 
that recordings were of sufficient length using the equation (Venglarik et al., 1994): 
 
   Trecord = (3o / N) / (Po)N,   (Eq. 3) 
 
where, Trecord is the time required to observe at least one single all-open event; o, the open time 
constant; N, the number of active channels and Po, the open probability.  For example, under 
the experimental conditions employed o = 27.8 ± 4.0 ms and Po = 0.073 ± 0.03 (means ± SD; 
n = 2) for F508del-CFTR determined using membrane patches with only a single active 
channel.  Using these data, 1.1 s are required to detect 1 F508del-CFTR channel in a membrane 
patch, 7.8 s are required to detect 2 channels, 71 s are required to detect 3 channels, 734 s are 
required to detect 4 channels and 8,046 s are required to detect 5 channels.  Thus, under our 
experimental conditions single-channel recordings lasting ~15 minutes will determine whether 
a membrane patch contains 4, but not 5 active F508del-CFTR Cl- channels. 
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 Single-channel currents were initially recorded on digital audiotape using a digital tape 
recorder (model DTR-1204, Biologic Scientific Instruments; Intracel Ltd., Royston, UK) at a 
bandwidth of 10 kHz.  On playback, records were filtered with an eight-pole Bessel filter 
(model F-900C/9L8L, Frequency Devices Inc., Ottawa, IL, USA) at a corner frequency (fc) of 
500 Hz and acquired using a DigiData1320A interface (Molecular Devices, CA, USA) and 
pCLAMP software at a sampling rate of 5 kHz.  To measure single-channel current amplitude 
(i), Gaussian distributions were fit to current amplitude histograms.  For Po and burst analyses, 
lists of open- and closed-times were created using a half-amplitude crossing criterion for event 
detection and dwell-time histograms constructed as previously described (Sheppard & 
Robinson, 1997); transitions < 1 ms were excluded from the analysis (eight-pole Bessel filter 
rise time (T10-90) ~0.73 ms at fc = 500 Hz).  Histograms were fitted with one or more component 
exponential functions using the maximum likelihood method.  For burst analyses, we used a tc 
(the time that separates interburst closures from intraburst closures) determined from closed 
time histograms (wild-type CFTR, tc = 14.5 ± 1.5 ms, n = 5; F508del-CFTR, tc = 20.5 ± 0.8 ms, 
n = 18; F508del-G550E-CFTR, tc = 17.6 ± 1.2 ms, n = 4; F508del-R1070W-CFTR, tc = 13.4 ± 
0.8 ms, n = 4; F508del-G550E-R1070W-CFTR, tc = 18.8 ± 1.0 ms, n = 4) (Cai et al., 2006).  
The mean interburst interval (TIBI) was calculated using the equation (Cai et al., 2006): 
 
   Po = Tb / (TMBD + TIBI),   (Eq. 4) 
 
where, Tb = (mean burst duration) x (open probability within a burst).  Mean burst duration 
(TMBD) and open probability within a burst (Po(burst)) were determined directly from 
experimental data using pCLAMP software.  For wild-type CFTR and revertant mutations, only 
membrane patches that contained a single active channel were used for burst analysis, whereas 
for F508del-CFTR, membrane patches contained no more than 3 active channels.  We analyzed 
only bursts of single-channel openings with no superimposed openings that were separated 
from one another by a time interval ≥ tc.  For the purpose of illustration, single-channel records 
were filtered at 500 Hz and digitized at 5 kHz before file size compression by 5-fold data 
reduction. 
 
Reagents 
 The dual-acting small molecule CFFT-004 and the CFTR corrector C18 were generous 
gifts of EPIX Pharmaceuticals Inc. and Cystic Fibrosis Foundation Therapeutics (CFFT) 
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(Bethesda, MD, USA) and RJ Bridges (Rosalind Franklin University of Medicine and Science) 
and CFFT, respectively, whereas the CFTR corrector lumacaftor (VX-809) and the CFTR 
potentiator ivacaftor (VX-770) were acquired from Selleck Chemicals (Houston, TX, USA).  
PKA purified from bovine heart was purchased from Calbiochem (Merck Chemicals Ltd., 
Nottingham, UK).  All other chemicals were of reagent grade and supplied by the Sigma-
Aldrich Company Ltd. (Gillingham, UK). 
 
 ATP was dissolved in intracellular solution, forskolin and genistein in ethanol, while all 
other reagents were dissolved in DMSO.  Stock solutions were stored at –20 °C except for that 
of ATP, which was prepared freshly before each experiment.  Immediately before use, stock 
solutions were diluted to final concentration and, where necessary, the pH of the intracellular 
solution was readjusted to pH 7.3 to avoid pH-dependent changes in CFTR function (Chen et 
al., 2009).  Precautions against light sensitive reactions were observed when using CFTR 
modulators.  DMSO was without effect on CFTR activity (Sheppard & Robinson, 1997).  On 
completion of experiments, the recording chamber was thoroughly cleaned before re-use (Wang 
et al., 2014). 
 
Statistics 
 The data and statistical analyses used in this study comply with the recommendations 
on experimental design and data analysis in pharmacology (Curtis et al., 2015), with the 
exception that some group sizes were unequal due to the technical difficulties with the 
acquisition of single-channel data.  Data recording and analyses were randomized, but not 
blinded.  Results are expressed as means ± SEM of n observations, except Figures 1, 9 and 
Supporting Information Figure S5, where data are means ± SD.  To test for differences between 
two groups of data acquired within the same experiment, we used Student’s paired t-test.  To 
test for differences between multiple groups of data, we used an analysis of variance (ANOVA) 
followed by post hoc tests.  All tests were performed using SigmaPlotTM (version 13.0; Systat 
software Inc., San Jose, CA, USA).  Differences were considered statistically significant when 
p < 0.05.  Data subject to statistical analysis had n values ≥ 5 per group.  In Western blotting 
experiments (Figure 2), n represents the number of Western blots; in Ussing chamber and Ieq 
studies (Figures 1, 5, 9, S2 and S4), n represents the number of polarised epithelia and in patch-
clamp experiments (Figures 3, 4 and 6 – 8 and Figures S1, S3 and S5), n represents the number 
of individual membrane patches obtained from different cells.  To avoid pseudo-replication, all 
experiments were repeated at different times. 
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Data accessibility statement 
Data associated with this manuscript will be made available through the Figshare repository. 
 
RESULTS 
CFFT-004 is a dual-acting CFTR modulator with independent CFTR corrector and 
CFTR potentiator activities 
 In this study, we investigated the impact of the dual-acting small molecule CFFT-004 
(from WO2010/068863) on F508del-CFTR using BHK cells expressing recombinant CFTR 
and primary cultures of hBE cells expressing native CFTR.  By Western blotting, we explored 
the effects of CFFT-004 on CFTR processing and with single-channel recording and the Ussing 
chamber technique, we analysed its action on channel gating and plasma membrane stability. 
 
 The original evidence that CFFT-004 and related compounds (e.g. CFFT-001; Hudson 
et al., 2012) are dual-acting small molecules was obtained from Ussing chamber studies of 
F508del-CFTR expressing FRT epithelia.  Figure 1A shows Isc recordings acquired at 37 °C 
from FRT epithelia incubated for 24 h at 37 °C with either the vehicle (DMSO 0.1% v v-1), 
lumacaftor (3 M), or CFFT-004 (0.1 – 30 M [its limit of solubility]) to investigate the action 
of CFFT-004 as a CFTR corrector and as a dual-acting small molecule.  Addition of forskolin 
(10 M) to vehicle-incubated FRT epithelia elicited basal CFTR-mediated Cl- currents, which 
were weakly increased by the CFTR potentiator genistein (20 M) and inhibited by the CFTR 
inhibitor CFTRinh-172 (20 M) (Figure 1A; black trace).  Addition of forskolin (10 M) to 
lumacaftor-treated F508del-CFTR-expressing FRT epithelia elicited substantial CFTR-
mediated Cl- current (Figure 1A; red trace).  Following decay of the transient (likely caused by 
a change in the electrochemical gradient across FRT epithelia following CFTR activation), 
acute addition of genistein (20 M) produced a large sustained increase in CFTR-mediated Cl- 
current followed by a progressive decline (Figure 1A; red trace), representing both the plasma 
membrane instability of F508del-CFTR at 37 °C (e.g. Wang et al., 2011; Liu et al., 2012; Meng 
et al., 2017) and the inhibitory effects of genistein on fully activated CFTR Cl- channels 
(Lansdell et al., 2000).  All CFTR-mediated Cl- current rescued by lumacaftor was fully 
inhibited by CFTRinh-172 (20 M) (Figure 1A and C). 
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 For F508del-CFTR-expressing FRT epithelia treated with CFFT-004 (0.1 – 3 M), the 
magnitude of the forskolin-stimulated transient was smaller than that observed when F508del-
CFTR was rescued with lumacaftor (3 M) and the response to acute addition of genistein (20 
M) was modest at best (Figure 1A).  By contrast, when F508del-CFTR-expressing FRT 
epithelia were treated with CFFT-004 (10 and 30 M), the magnitude of the forskolin-
stimulated transient was similar to or greater than that observed in lumacaftor-rescued F508del-
CFTR-expressing FRT epithelia and acute addition of genistein (20 M) only inhibited CFTR 
Cl- current (Figure 1A).  Figure 1B shows concentration-response relationships for F508del-
CFTR rescue by CFFT-004 derived from the data in Figure 1A and those from a second 
experiment (data not shown).  Assuming that CFFT-004 interacts with a single site on F508del-
CFTR (i.e. the Hill coefficient (H) = 1), the drug concentration required for half-maximal 
correction of F508del-CFTR is 11.8 ± 2.2 M (n = 4), while that required for half-maximal 
correction-potentiation is 8.3 ± 1.2 M (n = 4). 
 
 Figure 1C shows Isc recordings acquired at 37 °C from lumacaftor-rescued F508del-
CFTR-expressing FRT epithelia acutely treated with CFFT-004 (0.03 – 30 M) to investigate 
its action as a CFTR potentiator.  CFFT-004 (0.03 – 0.3 M) was without effect on CFTR-
mediated Cl- current, whereas subsequent acute addition of genistein (20 M) initially increased 
CFTR-mediated Cl- current, but this was promptly followed by a progressive decline of current 
(Figure 1C).  By contrast, CFFT-004 (1 – 30 M) generated progressively larger enhancements 
of CFTR-mediated Cl- current after which potentiation by genistein (20 M) became 
increasingly weaker and current inhibition became the drug’s predominant effect (Figure 1C).  
Figure 1D shows the concentration-response relationship for F508del-CFTR potentiation by 
CFFT-004 derived from the data in Figure 1C and those from a second experiment (data not 
shown).  Assuming that CFFT-004 interacts with a single site on F508del-CFTR, the drug 
concentration required for half-maximal potentiation is 1.6 ± 0.2 M (n = 4).  Thus, the data 
suggest that comparable concentrations of CFFT-004 are required for it to correct, potentiate 
and act as a dual-acting small molecule for F508del-CFTR. 
 
Differential effects of CFFT-004 on F508del-CFTR protein processing, stability and 
channel gating 
 To investigate how CFFT-004 acts as a dual-acting small-molecule, we studied its 
effects on F508del-CFTR heterologously expressed in BHK cells.  Figure 2 demonstrates that 
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wild-type CFTR generated band C, the mature, fully-glycosylated form of CFTR protein, 
whereas F508del-CFTR produced none.  Incubation of F508del-CFTR expressing BHK cells 
with CFFT-004 (5 M) for 24 h at 37 °C generated little mature CFTR protein (1% wild-type 
CFTR), whereas incubation with the CFTR corrector C18 (5 M), an analogue of lumacaftor 
(Eckford et al., 2014), for 24 h at 37 °C produced 21% wild-type CFTR (Figure 2).  Thus, 
CFFT-004, at best, modestly improves F508del-CFTR processing in recombinant BHK cells. 
 
 To investigate the single-channel behaviour of F508del-CFTR rescued by CFFT-004, 
we studied excised inside-out membrane patches from F508del-CFTR expressing BHK cells 
incubated at 27 °C for 24 – 72 h or treated with CFFT-004 (5 M) for 24 h at 37 °C.  All single-
channel recordings were acquired at 37 °C.  Consistent with previous results (for review, see 
Cai et al., 2011), Figures 3 and S1 demonstrate that the F508del mutation is without effect on 
current flow through open CFTR Cl- channels, but perturbs channel gating.  The gating pattern 
of wild-type CFTR is characterized by bursts of channel openings interrupted by brief, flickery 
closures, separated by longer closures between bursts (Figure 3A and S1A).  Figure 3B, F, G 
and S1B, D, E reveal that the F508del mutation decreases greatly the frequency of bursts of 
channel openings and concomitantly shortens their duration.  When tested as a CFTR 
potentiator by acute addition to the intracellular solution bathing excised membrane patches, 
CFFT-004 (5 M) enhanced both wild-type and F508del-CFTR channel gating (Figure S1).  
CFFT-004 (5 M) increased the frequency (by reducing interburst interval [IBI] 50%) and 
duration (by prolonging mean burst duration [MBD] 85%) of F508del-CFTR channel openings 
to enhance open probability (Po) 2-fold (Figure S1).  However, CFFT-004 did not restore the 
Po of F508del-CFTR to wild-type levels unlike ivacaftor (e.g. Wang et al., 2014) (Figures 8F 
and S1C). 
 
 When tested as a CFTR corrector, CFFT-004 (5 M) enhanced the Po of F508del-CFTR 
1.4-fold compared to low temperature rescue, albeit Po was still only one third that of wild-type 
CFTR (Figure 3).  Correction with CFFT-004 (5 M) increased F508del-CFTR Po by reducing 
IBI 23% and increasing MBD 100% (Figure 3E-G).  Of note, subsequent acute addition of 
CFFT-004 (5 M) to the intracellular solution to explore its action as a CFTR corrector-
potentiator led to a further enhancement of Po (1.8-fold vs. correction alone) as a result of an 
additional 58% reduction in IBI (Figure 3E-G).  Thus, when tested as a CFTR corrector-
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potentiator, CFFT-004 (5 M) increased the Po of F508del-CFTR 3.2-fold compared to low 
temperature rescue to achieve a level of channel activity 51% that of wild-type CFTR. 
 
 In contrast to the action of CFFT-004, correction with C18 (5 M) for 24 h at 37 °C did 
not enhance the Po of F508del-CFTR compared with that of low temperature rescue (p = 0.16) 
(Figure 3).  Moreover, acute addition of C18 (5 M) to the intracellular solution after C18-
induced correction was without effect on F508del-CFTR channel gating (Figure 3).  Thus, 
CFFT-004, but not C18, acts as a dual-acting small-molecule, modifying F508del-CFTR 
channel gating when tested as either a CFTR corrector or a CFTR potentiator.  In both cases, 
although IBI values remained greatly prolonged, CFFT-004 restored the MBD values to wild-
type levels (Figures 3 and S1). 
 
 One facet of the F508del-CFTR instability defect is channel rundown (deactivation) at 
37 °C in the presence of PKA and ATP (e.g. Wang et al., 2011; Liu et al., 2012; Meng et al., 
2017).  To investigate whether CFFT-004 rescues F508del-CFTR instability, we monitored the 
duration of channel activity in excised membrane patches at 37 °C by measuring Po once 
channels were fully activated by PKA-dependent phosphorylation.  Wild-type CFTR exhibited 
robust, sustained channel activity characterized by Po values of ~0.5 (Figure 4).  By contrast, 
the greatly reduced channel activity of F508del-CFTR was unstable, declining from Po values 
of ~0.15 to zero within 8 minutes (Figure 4B).  Figure 4C and D demonstrates that potentiation 
or correction of F508del-CFTR with CFFT-004 (5 M) elevated the initial Po of F508del-CFTR 
without improving the mutant protein’s stability in excised membrane patches.  Similarly, 
correction with C18 (5 M) failed to improve F508del-CFTR stability in excised membrane 
patches (Figure 4E). 
 
 To investigate further the action of CFFT-004 on the plasma membrane instability of 
F508del-CFTR, we studied CFTR-mediated transepithelial Cl- currents in FRT epithelia 
expressing F508del-CFTR.  We analysed the stability of F508del-CFTR Cl- currents after 
rescuing the apical membrane expression of F508del-CFTR by treating FRT epithelia with 
either CFFT-004 (10 M) or C18 (5 M) for 24 h at 37 °C.  Because of the modest amount of 
mature CFTR protein rescued by CFFT-004 (Figure 2), we did not attempt to evaluate 
biochemically the plasma membrane stability of F508del-CFTR rescued by the small molecule 
and we increased the concentration of drug used in these functional studies.  To specifically 
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investigate the bulk population of CFTR Cl- channels present at the plasma membrane, we 
treated FRT epithelia with the protein synthesis inhibitor cycloheximide (50 g ml-1) 15 minutes 
prior to mounting FRT epithelia in Ussing chambers and recording CFTR-mediated 
transepithelial Cl- currents at t = 0 h.  The remaining FRT epithelia were incubated with 
cycloheximide (50 g ml-1) for 2, 4 or 6 h prior to use.  After 6 h incubation, cycloheximide 
decreased Rt 1.8-fold in CFFT-004-rescued F508del-CFTR-expressing FRT epithelia, whereas 
after the same period, it increased Rt 2.1-fold in C18-rescued F508del-CFTR-expressing FRT 
epithelia (Figure 5B).  These data suggest that cycloheximide treatment did not impair epithelial 
integrity over the period of study. 
 
 Figures 5A and S2A - D show representative recordings of CFTR-mediated Cl- currents 
in F508del-CFTR-expressing FRT epithelia after rescue by C18 or CFFT-004 at different time 
intervals after cycloheximide treatment.  For C18-rescued F508del-CFTR, at t = 0 h forskolin 
(10 M) stimulated small CFTR Cl- currents, which were potentiated 7-fold by ivacaftor (1 
M) (Figure 5A).  By contrast, for CFFT-004-rescued F508del-CFTR, at t = 0 h forskolin (10 
M) stimulated large CFTR Cl- current (4.7-fold greater than those in C18-rescued F508del-
CFTR-expressing FRT epithelia), which were only modestly increased by ivacaftor (1 M) 
(Figure 5A).  Using the approach of Pedemonte et al. (2011), we quantified the different 
responses of C18- and CFFT-004-rescued F508del-CFTR to forskolin and ivacaftor (Figure 
5C).  For CFFT-004, the forskolin- stimulated Cl- current represented ~90% of the total CFTR-
mediated Cl- current at all time points tested, whereas for C18, it was only ~25%.  The 
agreement of these results with those of Pedemonte et al. (2011) provide further evidence that 
CFFT-004 is a dual-acting small molecule that corrects and potentiates F508del-CFTR.  The 
data also provide an additional explanation for the modest effects of genistein after F508del-
CFTR rescue by CFFT-004 (Figure 1). 
 
 Figures 5D and E show the magnitude of forskolin-stimulated and total CFTR-mediated 
Cl- current at different times after FRT epithelia were treated with cycloheximide (50 g ml-1).  
For C18-rescued F508del-CFTR, the magnitude of forskolin-stimulated CFTR Cl- current was 
constant over the 6 h period (Figure 5D).  By contrast, for CFFT-004-rescued F508del-CFTR, 
the magnitude of forskolin-stimulated CFTR Cl- current was enhanced greatly at t = 0 h (3.5-
fold larger than that in C18-rescued F508del-CFTR-expressing FRT epithelia), but declined 
progressively over the 6 h period to a level similar to that of the forskolin-stimulated CFTR Cl- 
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current of C18-rescued F508del-CFTR (Figure 5D).  For both CFFT-004- and C18-rescued 
F508del-CFTR, the total CFTR-mediated Cl- current declined with a similar time course over 
the 6 h period (Figure 5E), which was comparable to that observed with CFTR Cl- currents 
acutely potentiated by ivacaftor in F508del-CFTR-expressing FRT epithelia rescued by 
lumacaftor (Meng et al., 2017).  We interpret these data to suggest that CFFT-004 does not 
rescue the stability defect of F508del-CFTR in intact cells. 
 
 We previously observed a CFTR-dependent enhanced basal Isc in Ussing chamber 
recordings of CFTR-expressing FRT epithelia chronically treated with ivacaftor (Meng et al., 
2017).  We were therefore interested to learn whether CFFT-004 influences the magnitude of 
basal Isc in Ussing chamber studies.  Figure 5F demonstrates noticeable basal Isc at all time 
points after cycloheximide treatment in CFFT-004-rescued F508del-CFTR-expressing FRT 
epithelia, but for those rescued by C18, only at t = 0 and 2 h.  Of note, the magnitude of basal 
Isc observed with CFFT-004 exceeded that which we observed previously for F508del-CFTR 
treated chronically with ivacaftor (Figure 5F and Meng et al., 2017).  Like the basal Isc observed 
after chronic ivacaftor treatment (Meng et al., 2017), that recorded in F508del-CFTR-
expressing FRT epithelia pre-treated with CFFT-004 was CFTRinh-172-sensitive (Figure 5G 
and S2), indicating that it is CFTR-dependent.  In conclusion, CFFT-004 has diverse effects as 
a dual-acting small-molecule.  It strongly potentiates F508del-CFTR channel gating, modestly 
affects F508del-CFTR protein processing, but is without effect on its plasma membrane 
stability defect. 
 
Use of revertant mutations to explore the mechanism of action of CFFT-004 
 Previous work investigated the rescue of F508del-CFTR by revertant mutations, which 
repair defects in NBD1 and the NBD-membrane-spanning domain (MSD) interface to restore 
its plasma membrane expression, stability and function (Roxo-Rosa et al., 2006; Mendoza et 
al., 2012; Rabeh et al., 2012; Farinha et al., 2013a).  To understand better how CFFT-004 
rescues F508del-CFTR, we studied the revertant mutations G550E, R1070W and G550E-
R1070W (deCarvalho et al., 2002; Thibodeau et al., 2010).  Farinha et al. (2013a) demonstrated 
that in BHK cells the combination revertant G550E-R1070W restored F508del-CFTR 
maturation to ~80% that of wild-type CFTR.  Figure 6 shows the effects of the G550E, R1070W 
and G550E-R1070W mutations on F508del-CFTR channel gating and Figure S3 their effects 
on F508del-CFTR stability in BHK cells.  Consistent with previous results (Roxo-Rosa et al., 
2006), G550E enhanced greatly both the frequency and duration of F508del-CFTR channel 
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openings with the result that its Po was 1.3-fold higher than that of wild-type CFTR (Figure 6).  
By contrast, R1070W conferred on F508del-CFTR the gating behaviour of wild-type CFTR; 
values of Po, MBD and IBI of F508del-R1070W-CFTR did not differ significantly from those 
of wild-type CFTR (p ≥ 0.45) (Figure 6).  However, the combination revertant G550E-R1070W 
elevated F508del-CFTR channel activity to levels that exceeded greatly those of wild-type 
CFTR; the 13.5-fold increase in Po compared with that of F508del-CFTR was achieved by an 
8.5-fold enhancement of MBD and a 22.1-fold reduction in IBI (Figure 6).  In contrast to the 
different effects of revertant mutations on F508del-CFTR channel gating, G550E, R1070W and 
G550E-R1070W all stabilized F508del-CFTR channel activity in excised inside-out membrane 
patches.  Figure S3 demonstrates that over the period of the experiment, there was no difference 
between the three revertant mutations, all restored wild-type levels of stability to F508del-
CFTR at 37 °C. 
 
 To investigate the mechanism of action of CFFT-004, we tested its effects on the 
F508del-CFTR revertant mutations.  Figure 7A – C shows representative single-channel 
recordings and Figure 7D – F mean data for CFFT-004 tested as a potentiator, a corrector and 
as a dual-acting small molecule.  When tested as a potentiator, either alone or after correction 
(i.e. as a dual-acting small molecule), CFFT-004 (5 M) enhanced the Po of each of the three 
F508del-CFTR revertants, albeit the increase was minimal with F508del-G550E-R1070W 
(Figure 7D – F).  By contrast, when tested as a corrector, CFFT-004 (5 M) enhanced the Po of 
F508del-R1070W, but not F508del-G550E nor F508del-G550E-R1070W (Figure 7D – F).  We 
interpret these data to suggest that correction, but not potentiation, by CFFT-004 might involve 
G550 and hence, NBD1. 
 
Action of CFFT-004 on the CF mutant A561E-CFTR 
 To explore the specificity of CFFT-004, we tested its effects on A561E, another class 
II-III-VI CF mutation (Veit et al., 2016) found in NBD1 with closely comparable defects as 
F508del-CFTR (Mendes et al., 2003; Wang et al., 2014).  Figures 2 and 8 demonstrate that 
when BHK cells expressing either F508del- or A561E-CFTR were grown at 37 °C no mature 
protein was produced and no channel activity observed.  However, the two CF mutants 
exhibited different responses to CFFT-004 and C18.  When BHK cells expressing A561E-
CFTR were incubated with either CFFT-004 (5 M) or C18 (5 M) for 24 h at 37 °C, there was 
no improvement in A561E-CFTR maturation or function in contrast to the effects of the small 
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molecules on F508del-CFTR.  Figure 2 demonstrates that there was no increase in band C, the 
mature fully-glycosylated form of CFTR protein using either small-molecule.  Figure 8E shows 
that the Po of A561E was reduced compared to that of F508del-CFTR when treated with CFFT-
004 (5 M) or C18 (5 M) as a CFTR corrector.  Furthermore, CFFT-004 failed to enhance 
A561E-CFTR channel gating when tested as a CFTR potentiator.  The Po of low temperature-
rescued A561E-CFTR Cl- channels was unaffected when CFFT-004 (5 M) was added acutely 
to the intracellular solution (Figure 8F).  By contrast, ivacaftor (1 M) potentiated strongly 
A561E-CFTR channel gating, restoring Po to wild-type levels like its effect on F508del-CFTR 
(Wang et al., 2014) (Figure 8F).  Thus, despite the similar effects of the two mutations on 
CFTR, at the concentrations tested, CFFT-004 rescues F508del-CFTR, but not A561E-CFTR. 
 
CFFT-004 has dual-activity on native F508del-CFTR Cl- channels 
 The primary site of disease in CF is the respiratory airways.  Therefore, we sought to 
determine whether CFFT-004 has dual-activity on native F508del-CFTR Cl- channels using 
epithelia of hBE cells from CF patients homozygous for F508del-CFTR.  Figure 9 shows Ieq 
and Isc measurements from epithelia of F508del-CFTR-expressing hBE cells acquired at 37 °C. 
 
 Figure 9A compares the correction of native F508del-CFTR in hBE cells by CFFT-004 
and lumacaftor.  After inhibition of ENaC with benzamil (6 M), forskolin (10 M) stimulated 
a large transient increase in Ieq in epithelia of F508del-CFTR-expressing hBE cells pre-treated 
with CFFT-004 (10 M) for 24 h at 37 °C (Figure 9A; pink trace).  The ~5-fold difference in 
forskolin-stimulated Ieq in CFFT-004-treated epithelia of F508del-CFTR-expressing hBE 
cells compared with DMSO-treated epithelia is the result of both CFFT-004-mediated 
correction and potentiation of F508del-CFTR.  Like the effects of CFFT-004 correction on FRT 
epithelia expressing F508del-CFTR (Figures 1 and 5), the potentiation of the forskolin response 
is likely due to the slow removal of CFFT-004 from hBE cells.  By contrast, the ~2-fold 
difference in CFTR-mediated Cl- current inhibited by CFTRinh-172 (20 M) between the CFFT-
004-treated (pink trace) and vehicle-treated (black trace) epithelia of F508del-CFTR hBE cells 
in Figure 9A reflects the increased number of F508del-CFTR Cl- channels at the apical 
membrane of CFFT-004-treated hBE cells.  Although the magnitude of forskolin-stimulated 
CFTR-mediated Cl- current rescued by CFFT-004 (10 M) was similar to that corrected with 
lumacaftor (3 M), the CFFT-004-rescued Ieq declined progressively, whereas the lumacaftor-
rescued Ieq persisted (Figure 9A).  As a result, the CFTRinh-172-sensitive Ieq elicited by 24 h 
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treatment with CFFT-004 (10 M) compared to its vehicle (DMSO, 0.1% v v-1) was only one 
quarter that of the lumacaftor-rescued Ieq (Figure 9A).  Thus, CFFT-004 corrected native 
F508del-CFTR in hBE cells with 25% of the efficacy of lumacaftor. 
 
 Figure 9B compares potentiation of lumacaftor-rescued native F508del-CFTR in hBE 
cells by CFFT-004 and ivacaftor.  After inhibition of ENaC-mediated Isc with benzamil (6 M) 
and activation of CFTR-mediated transepithelial Cl- current with forskolin (10 M), the effects 
of CFTR potentiators were tested on steady-state CFTR Cl- currents.  Ivacaftor (1 M) elicited 
a large transient current, which declined to a steady-state ~2-fold larger than that achieved by 
forskolin alone (Figure 9B).  By contrast, CFFT-004 (1 M) had little or no effect, whereas 
CFFT-004 (3 and 10 M) potentiated similar amounts of CFTR-mediated Cl- current, achieving 
steady-state currents about half of those of ivacaftor (Figure 9B).  Subsequent addition of 
genistein (20 M) after CFFT-004 or ivacaftor potentiated currents to a level comparable with 
the ivacaftor transient after which currents declined progressively before inhibition by CFTRinh-
172 (20 M) (Figure 9B).  To compare potentiator efficacy, we measured the change in current 
elicited by potentiators relative to that of forskolin.  For ivacaftor (1 M), Isc VX-770 / Isc Fsk = 
2.0, while for CFFT-004 (3 and 10 M), Isc CFFT-004 / Isc Fsk = 1.3 and 1.2, respectively (Isc 
DMSO / Isc Fsk = 0.9).  Thus, when corrected for the vehicle response (DMSO, 0.1% v v-1), CFFT-
004 potentiated native F508del-CFTR in hBE cells with ~40% of the efficacy of ivacaftor. 
 
 Finally, we investigated the effects of CFFT-004 on native A561E-CFTR Cl- currents 
using epithelia of hBE cells from CF patients homozygous for A561E-CFTR (Supporting 
Information Results and Figure S4).  As a control, we studied hBE cells from CF patients 
homozygous for F508del-CFTR.  Consistent with the data in Figure 9 and our studies of 
recombinant F508del- and A561E-CFTR (Figures 2 and 8), CFFT-004 rescued F508del-CFTR, 
but not A561E-CFTR in epithelia of hBE cells (Figures S4).  We conclude that CFFT-004 
corrects and potentiates native F508del-CFTR Cl- channels. 
 
DISCUSSION 
 This study investigated the rescue of native and recombinant F508del-CFTR by the 
CFTR corrector-potentiator CFFT-004.  CFFT-004 partially restored channel gating to 
F508del-CFTR, but only modestly improved plasma membrane expression and failed to rescue 
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its stability defect.  These data argue that one small molecule might not be enough to rescue 
completely CF mutants. 
 
 Previous work identified two types of CFTR corrector-potentiators.  The first group of 
dual-acting small molecules (e.g. aminoarylthiazoles; Pedemonte et al., 2011) promote the 
trafficking of F508del-CFTR to the plasma membrane in the same way as exemplar CFTR 
correctors (e.g. the bisaminomethylbithiazole corr-4a; Pedemonte et al., 2005).  However, 
aminoarylthiazoles are atypical CFTR potentiators, which require protein synthesis before they 
augment CFTR channel activity (Pedemonte et al., 2011).  Building on these studies, Eckford 
et al. (2014) demonstrated that the CFTR correctors lumacaftor and C18 exert posttranslational 
effects on F508del-CFTR in addition to acting co-translationally to allow F508del-CFTR to 
traffic to the plasma membrane.  Pretreatment with lumacaftor and C18 accelerated F508del-
CFTR activation by PKA-dependent phosphorylation, while C18 enhanced both ATP-
dependent and independent channel activity of phosphorylated purified F508del-CFTR protein 
(Eckford et al., 2014).  Our observation that CFFT-004 acutely potentiates F508del-CFTR 
channel gating after rescue by either low temperature incubation or CFFT-004 pretreatment 
argues that the mechanism of action of CFFT-004 is distinct from aminoarylthiazoles, 
lumacaftor and C18, which possess typical CFTR corrector activity, but atypical CFTR 
potentiator action.  The enhancement of F508del-CFTR Po achieved by pretreatment with 
CFFT-004 compared to low temperature rescue, argues that this small molecule interacts 
directly with F508del-CFTR to partially repair the structural defects responsible for aberrant 
channel gating.  By contrast, correction with lumacaftor did not enhance F508del-CFTR Po 
compared to low temperature rescue (Kopeikin et al., 2014; Meng et al., 2017). 
 
 A second class of dual-acting small molecules, cyanoquinolines, with independent 
CFTR corrector and CFTR potentiator activities, was identified by Phuan et al. (2011).  One 
cyanoquinoline, CoPo-22 trafficked F508del-CFTR to the plasma membrane with comparable 
efficacy to the CFTR corrector corr-4a and potentiated F508del-CFTR-mediated apical 
membrane Cl- currents after low temperature rescue with efficacy similar to the CFTR 
potentiator genistein (Phuan et al., 2011).  Although we did not directly compare the effects of 
CFFT-004 and CoPo-22, several lines of evidence suggest that CFFT-004 is a dual-acting small 
molecule with independent CFTR corrector and CFTR potentiator activities.  First, CFFT-004 
corrected and potentiated F508del-CFTR activity in both FRT epithelia and BHK cells 
expressing recombinant CFTR as well as epithelia of CF patient-derived hBE cells.  Second, 
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albeit with differing efficacies, CFFT-004 rescued F508del-CFTR expression biochemically 
and functionally.  Third, correction with CFFT-004 improved F508del-CFTR channel gating 
compared to low temperature-rescued F508del-CFTR.  Fourth, single-channel studies 
demonstrated that CFFT-004 acutely potentiated F508del-CFTR channel gating following 
CFFT-004-mediated rescue of F508del-CFTR expression.  Finally, the F508del-CFTR 
revertant mutation G550E abrogated correction, but not potentiation by CFFT-004.  Taken 
together, the simplest interpretation of these data is that CFFT-004 is a CFTR corrector-
potentiator capable of independently restoring the plasma membrane expression of F508del-
CFTR and potentiating its channel gating. 
 
 An important finding of this study is the differential effects of CFFT-004 on the protein 
processing, plasma membrane stability and channel gating defects of F508del-CFTR.  CFFT-
004 robustly improved F508del-CFTR channel gating in recombinant BHK cells, albeit without 
restoring the wild-type pattern of channel gating.  By contrast, using recombinant BHK cells 
its effects on F508del-CFTR protein processing (as measured by production of mature CFTR 
protein) were modest at best and it was without effect on the plasma membrane stability of 
F508del-CFTR.  One possible interpretation of these results might be that CFFT-004 promotes 
the traffic of immature F508del-CFTR protein to the plasma membrane by an unconventional 
secretory pathway (Gee et al., 2011).  However, F508del-CFTR is only delivered to the plasma 
membrane by this route when the conventional secretory pathway is inhibited (Gee et al., 2011).  
We consider a more likely explanation for the different effects of CFFT-004 on F508del-CFTR 
expression and function the much higher sensitivity of single-channel recording to detect CFTR 
than Western blotting.  Single-channel studies quantify current flow through open channels and 
the pattern of channel gating.  They are not designed to provide information about CFTR 
expression levels.  For this purpose, it is necessary to measure macroscopic CFTR Cl- currents 
by whole-cell recording or the Ussing chamber technique.  Indeed, by studying CFTR-mediated 
Cl- currents in F508del-CFTR expressing FRT epithelia, we found that comparable 
concentrations of CFFT-004 were required for F508del-CFTR correction and potentiation.  
Interestingly, similar results were previously reported for two other dual-acting small 
molecules, EN277I, an efficacious aminoarylthiazole (Pedemonte et al., 2011) and CoPo-22, 
the most active cyanoquinoline (Knapp et al., 2012). 
 
 Once delivered to the plasma membrane, F508del-CFTR exhibits reduced stability 
because of its reduced thermostability (e.g. Wang et al., 2011) and accelerated endocytosis (e.g. 
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Swiatecka-Urban et al., 2005). Although F508del-CFTR stability studies similar to our own 
were not performed, previous data suggest that aminoarylthiazoles and cyanoquinolines might 
rescue the stability defect of F508del-CFTR (Pedemonte et al., 2011; Phuan et al., 2011; Knapp 
et al., 2012).  Importantly, unlike some CFTR potentiators (e.g. ivacaftor; Cholon et al., 2014; 
Veit et al., 2014), there was no evidence of F508del-CFTR destabilization when dual-acting 
small molecules were tested as CFTR potentiators (Phuan et al., 2011; Knapp et al., 2012).  By 
contrast, CFFT-004 failed to rescue the plasma membrane stability of F508del-CFTR.  Like 
ivacaftor (Meng et al., 2017), in cell-free membrane patches, potentiation with CFFT-004 
accelerated F508del-CFTR deactivation (Figure 4B and C).  Moreover, in polarised epithelia 
F508del-CFTR correction with CFFT-004 elicited large forskolin-stimulated CFTR Cl- 
currents which declined over time (Figure 5D and E).  These data concur with the idea that the 
thermal instability of F508del-CFTR is related to its channel activity (Liu et al., 2012).  They 
also argue that unlike the action of revertant mutations (Figure S3), CFFT-004 does not repair 
the structural defects that cause F508del-CFTR thermoinstability. 
 
 An intriguing feature of our F508del-CFTR stability studies was the large CFTR-
dependent basal currents observed in Ussing chamber recordings of CFFT-004-rescued 
F508del-CFTR-expressing FRT epithelia.  We previously observed elevated basal currents in 
CFTR-expressing FRT epithelia treated chronically with ivacaftor (Meng et al., 2017).  
However, the basal currents observed with F508del-CFTR rescued by CFFT-004 were larger 
than those detected with ivacaftor (Figure 5F and Meng et al., 2017).  The simplest 
interpretation of these currents is that they represent CFFT-004 potentiation of F508del-CFTR 
Cl- channels activated by components of the culture media used to treat cells with small 
molecules.  A likely explanation for their absence in single-channel studies is the use of excised 
cell-free membrane patches, leading to the loss of cytosolic constituents. 
 
 Pedemonte et al. (2010) demonstrated that cell background influences F508del-CFTR 
rescue by CFTR correctors, but not CFTR potentiators.  For aminoarylthiazole and 
cyanoquinoline CFTR corrector-potentiators, there also appears to be some effect of cell 
background on F508del-CFTR rescue when they are tested as CFTR correctors (Pedemonte et 
al., 2011; Phuan et al., 2011).  For example, the aminoarylthiazole EN277I corrected F508del-
CFTR expression in recombinant FRT and A549 cells, but not recombinant CFBE41o- cells 
(Pedemonte et al., 2011).  Our own data do not exclude the possibility that cell background 
influences the action of CFFT-004.  Nevertheless, the finding that CFFT-004 acts as an 
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F508del-CFTR corrector in recombinant FRT and BHK cells and CF patient-derived hBE cells, 
suggests that it likely acts directly on F508del-CFTR. 
 
 More than 2,000 mutations have been identified in the CFTR gene 
(http://www.genet.sickkids.on.ca/cftr/), but not all cause disease.  Of the relatively small 
number that have been investigated, many affect CFTR in multiple ways (Veit et al., 2016), 
suggesting that efficacious CFTR corrector-potentiators would have wide application.  To begin 
to explore the action of CFFT-004 on other CF mutants, we selected for study A561E-CFTR.  
Like F508del, A561E causes a temperature-sensitive folding defect in NBD1 that perturbs 
CFTR processing, plasma membrane stability and channel gating (Mendes et al., 2003; Wang 
et al., 2014).  At the concentrations tested, CFFT-004 corrected and potentiated F508del-CFTR, 
but was without effect on A561E-CFTR.  One possible explanation for the data is that the 
processing defect caused by A561E is distinct from that of F508del and less amenable to rescue 
by revertant mutations (Roxo-Rosa et al., 2006) and the CFTR correctors lumacaftor and C18 
(Awatade et al., 2015; present study).  Interestingly, CFFT-004 was also without effect on 
murine F508del-CFTR (see Supporting Information Results and Figure S5) in agreement with 
other cross-species comparative studies of CFTR (Lansdell et al., 1998; Ostedgaard et al., 2007; 
Van Goor et al., 2009).  Taken together, the data highlight the challenge of identifying CFTR 
corrector-potentiators that target multiple CF mutations. 
 
 While dual-acting small molecules might act indirectly to rescue F508del-CFTR, the 
simplest interpretation of the data is that these agents interact directly with F508del-CFTR to 
repair folding and assembly defects and hence, improve its plasma membrane expression and 
channel gating.  Pedemonte et al. (2011) interpreted the similar effects of the aminoarylthiazole 
EN277I as a CFTR corrector and CFTR potentiator to suggest that it rescues F508del-CFTR 
expression and function by a common mechanism.  By contrast, Knapp et al. (2012) posited 
the idea of a single binding site for both the CFTR corrector and CFTR potentiator activities of 
cyanoquinolines that alters its conformation during the processing of F508del-CFTR and its 
delivery to the plasma membrane.  Interestingly, 4,6,4’-trimethylangelicin, a CFTR corrector-
potentiator with anti-inflammatory properties, exhibits independent corrector and potentiator 
activities similar to those of lumacaftor and ivacaftor and like lumacaftor interacts directly with 
MSD1 of CFTR (Tamanini et al., 2011; Loo et al., 2013; Ren et al., 2013; Favia et al., 2014; 
Laselva et al., 2016).  Similarly, thymosin 1, a naturally-occurring peptide, reduces 
inflammation, while restoring the expression and function of F508del-CFTR (Romani et al., 
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2017).  Because thymosin 1 is approved for clinical use as an immunomodulator (Goldstein 
& Goldstein, 2009), further studies comparing its action with clinically-used small molecule 
CFTR modulators should be prioritized. 
 
 In this study, we found that potentiation by CFFT-004 was unaffected by the F508del-
CFTR revertant mutations G550E and R1070W (deCarvalho et al., 2002; Roxo-Rosa et al., 
2006; Thibodeau et al., 2010; Farinha et al., 2013a), but correction was abolished by G550E.  
We interpret these data to suggest that correction by CFFT-004 involves amino acid sequences 
within NBD1, possibly ATP-binding site 2.  Interestingly, using in silico structure-based 
screening Kalid et al. (2010) hypothesized the locations of three potential binding sites for small 
molecules on F508del-CFTR: (i) the NBD1:NBD2 interface, (ii) the NBD1:ICL4 cavity formed 
by deletion of F508 and (iii) the NBD1-MSD2 and NBD2-MSD1 interfaces.  Following 
functional testing, Kalid et al. (2010) identified two CFTR corrector-potentiators: EPX-107979, 
binding at the NBD1-MSD2 and NBD2-MSD1 interfaces and EPX-108380, binding at the 
NBD1:NBD2 interface (Kalid et al., 2010).  Given the location of G550 within ATP-binding 
site 2 of CFTR (Lewis et al., 2004; Gadsby et al., 2006), CFFT-004 might bind at the same or 
a closely related site to EPX-108380.  However, NMR data revealed that the related dual-acting 
small molecule CFFT-001 interacts with  strands S3, S9 and S10 in NBD1 to promote NBD 
dimerization (Hudson et al., 2012).  Thus, an alternative explanation of our data is that the 
action of the G550E revertant on F508del-CFTR hinders access of CFFT-004 to its binding-
site, limiting the compound’s action. 
 
 In conclusion, CFFT-004 is a dual-acting small-molecule that independently promotes 
F508del-CFTR trafficking to the plasma membrane and boosts its channel activity in both 
heterologous cells and CF patient-derived hBE cells.  However, CFFT-004 exerts its effects 
differentially, improving noticeably F508del-CFTR channel gating, rescuing modestly protein 
processing, but failing to improve stability.  These data highlight the challenge of identifying a 
single small molecule that rescues all the different defects of F508del-CFTR with high efficacy 
and potency.  They also suggest that CFTR corrector-potentiators which target F508del-CFTR 
might be ineffective for other CF mutations that perturb CFTR protein processing and channel 
gating.  Thus, combinations of small molecules targeting the different defects of F508del-CFTR 
and other CF mutations might be the best strategy to develop transformational drug therapies 
for CF. 
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FIGURE LEGENDS 
Figure 1: CFFT-004 rescues F508del-CFTR function in recombinant FRT epithelia by 
acting both as a CFTR corrector and as a CFTR potentiator  (A, C) Ussing chamber 
recordings of Isc from FRT epithelia expressing F508del-CFTR acquired at 37 °C are shown.  
Prior to commencing the recordings, in A F508del-CFTR expressing epithelia were treated for 
24 h at 37 °C with either the vehicle DMSO (0.1% v v-1), CFFT-004 (0.1 – 30 M) or the CFTR 
corrector lumacaftor (VX-809; 3 M) as indicated, whereas in C, they were pre-treated with 
lumacaftor (VX-809; 3 M) for 24 h at 37 °C.  In A and C, during the indicated periods, 
forskolin (Fsk; 10 M), genistein (Gen; 20 M) and CFTRinh-172 (I172; 20 M) were added to 
the solutions bathing the apical and basolateral membranes, and in C, during the indicated 
period, either the vehicle DMSO (0.1% v v-1) or CFFT-004 (0.03 – 30 M) were added to the 
apical solution as indicated (Cmpd).  In both A and C, pre-forskolin baseline Isc was subtracted 
from all Isc recordings before data were averaged.  (B) Relationship between CFFT-004 
concentration and change in Isc for the peak forskolin response and the CFTRinh-172-sensitive 
current used to determine EC50 values for CFTR correction and potentiation and CFTR 
correction alone, respectively.  (D) Relationship between CFFT-004 concentration and 
normalised maximum acute response following CFFT-004 addition used to determine the EC50 
value for CFTR potentiation.  The normalised maximal acute response to CFFT-004 represents 
the slope corrected maximal acute response to CFFT-004 normalised to the forskolin-stimulated 
Isc at the time of CFFT-004 addition.  In A and C, data are means ± SD (n = 2), whereas in B 
and D, data are means ± SD (n = 4); error bars are smaller than symbol size except where shown.  
In B and D, the continuous lines show the fit of the Hill equation to mean data using a Hill 
coefficient (H) of 1. 
 
Figure 2: Differential effects of the small molecules CFFT-004 and C18 on the maturation 
of F508del- and A561E-CFTR expressed in BHK cells  (A) Representative Western blots of 
BHK cells stably expressing F508del- and A561E-CFTR are shown.  CF mutant-expressing 
BHK cells were treated with CFFT-004 (5 M), C18 (5 M) or the vehicle DMSO (0.05% v v-
1) for 24 h at 37 °C before cells were lysed and Western blotting performed; other CF mutant-
expressing BHK cells were untreated (ut).  Lysates from BHK cells stably expressing wild-type 
CFTR were used as a control.  CFTR was detected with the mouse anti-CFTR monoclonal 
antibody (596), which recognizes a region of NBD2 (1204 – 1211; Cui et al., 2007).  Arrows 
indicate the positions of the band B (immature) and C (mature) forms of CFTR.  (B) The amount 
39 
 
of CFTR protein present in the mature form (band C) is expressed as a percentage of total CFTR 
protein (% CFTR protein processed = [band C / (bands B + C) x 100]).  Data are means ± SEM 
(n = 13) expressed as a percentage of that of wild-type CFTR. 
 
Figure 3: CFFT-004 corrects and potentiates F508del-CFTR channel gating  (A – D) 
Representative single-channel records of wild-type and F508del-CFTR in excised inside-out 
membrane patches from BHK cells under the indicated experimental conditions.  ATP (1 mM) 
and PKA (75 nM) were continuously present in the intracellular solution.  When tested as 
correctors (cor) or dual-acting small molecules (cor-pot), CFFT-004 (CF4) and C18 were used 
at 5 M and either incubated with cells for 24 h at 37 °C or added acutely to the intracellular 
solution.  Prior to commencing channel recordings, cells incubated with CFFT-004 and C18 
were thoroughly washed to remove any residual small molecules from the extracellular 
solution; the maximum period cells were left in drug-free solution before study did not exceed 
30 minutes.  In C and D, the recordings are from the same membrane patches before and after 
testing CFFT-004 and C18 as potentiators.  Dotted lines indicate the closed channel state and 
downward deflections correspond to channel openings.  Unless otherwise indicated in this and 
other figures, membrane patches were voltage-clamped at –50 mV, there was a large Cl- 
concentration gradient across the membrane ([Cl-]int, 147 mM; [Cl-]ext, 10 mM) and temperature 
was 37 °C.  (E – G) Open probability (Po), mean burst duration (MBD) and interburst interval 
(IBI) of F508del-CFTR for the indicated conditions.  Data are means ± SEM (WT, n = 5; 
F508del 27 °C rescue, n = 18; F508del CFFT-004 correction, n = 6; F508del CFFT-004 dual-
action, n = 6; F508del C18 correction, n = 6; F508del C18 dual-action, n = 6); *, p < 0.05 vs. 
WT-CFTR; †, p < 0.05 vs. F508del-CFTR 27 °C rescue; ‡, p < 0.05 vs. CFFT-004 correction. 
 
Figure 4: Impact of CFFT-004 on the stability defect of F508del-CFTR in excised inside-
out membrane patches  (A – E) Time courses of Po for F508del-CFTR in excised membrane 
patches commenced once channel activation was complete for the indicated experimental 
conditions.  In B – E, left and right ordinates show Po (bars) and normalised Po (circles), 
respectively.  Wild-type CFTR channels were studied at 37 °C, whereas F508del-CFTR 
channels were activated at 27 °C before temperature was increased to 37 °C and Po measured.  
In C, F508del-CFTR was rescued at 27 °C before CFFT-004 (CF4; 5 M) was tested as a 
potentiator (pot) only.  In D and E, CFFT-004 (5 M; D) and C18 (5 M; E) were tested as 
correctors (cor) by incubation with cells for 24 h at 37 °C.  In D and E, prior to commencing 
40 
 
channel recordings, cells incubated with CFFT-004 and C18 were thoroughly washed to remove 
any residual small molecules from the extracellular solution.  Data are means ± SEM (WT, n = 
7; F508del 27 °C rescue, n = 10; F508del CFFT-004 potentiation, n = 6; F508del CFFT-004 
correction, n = 6; F508del C18 correction, n = 7).  In A and B, some data were originally 
published in Wang et al. (2014), copyright (2014) The British Pharmacological Society (A, n 
= 4; B, n = 5); other data are newly acquired.  Other details as in Figure 3. 
 
Figure 5: Impact of CFFT-004 on the stability of F508del-CFTR-mediated transepithelial 
Cl- currents  (A) Representative Ussing chamber recordings of F508del-CFTR showing the 
effects of correction with C18 and CFFT-004 on CFTR-mediated transepithelial Cl- currents.  
F508del-CFTR-expressing FRT epithelia were incubated for 24 h at 37 °C in the presence of 
either C18 (5 M) or CFFT-004 (10 M) without reducing the FBS concentration of media.  
Fifteen minutes prior to mounting FRT epithelia in Ussing chambers (i.e. t = 0 h – 15 min), 
they were treated with cycloheximide (50 g ml-1), added to both the apical and basolateral 
solutions.  At the indicated times, FRT epithelia were activated with forskolin (Fsk; 10 M), 
potentiated with ivacaftor (VX; 1 M) and inhibited by CFTRinh-172 (I172; 10 M); continuous 
lines indicate the presence of different compounds in the apical solution; cycloheximide (50 g 
ml-1) was present in the apical and basolateral solutions during Isc recordings.  Data are 
normalised to baseline current so that Isc represents the change in transepithelial current after 
CFTR activation by forskolin.  The vertical lines denote the forskolin-stimulated CFTR-
mediated Isc (IFsk) and the total CFTR-mediated Isc (ITot).  For representative CFTR-mediated 
transepithelial Cl- currents of C18- and CFFT-004-rescued F508del-CFTR recorded at different 
times after cycloheximide treatment, see Figure S2.  (B and C) Rt and magnitude of forskolin-
stimulated CFTR-mediated Isc (IFsk) expressed as a percentage of the total CFTR-mediated Isc 
(ITot) (i.e. IFsk/ITot) for F508del-CFTR-expressing FRT epithelia pre-treated with either C18 (5 
M) or CFFT-004 (10 M) for 24 h at 37 °C prior to study.  Fifteen minutes prior to t = 0 h, 
FRT epithelia were treated with cycloheximide (50 g ml-1) as described in A.  (D, E) 
Magnitude of forskolin-stimulated CFTR-mediated Isc and the total CFTR-mediated Isc (i.e. 
the ivacaftor potentiated Isc) for C18- and CFFT-004-rescued F508del-CFTR at different times 
after cycloheximide treatment.  (F) Magnitude of the absolute Isc prior to CFTR activation for 
C18- and CFFT-004-rescued F508del-CFTR at different times after cycloheximide treatment.  
(G) Magnitude of the residual CFTR-mediated Cl- current determine using CFTRinh-172 (10 
M) for C18- and CFFT-004-rescued F508del-CFTR at different times after cycloheximide 
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treatment.  For definition of residual CFTR-mediated Cl- current (IRes), see Figure S2E.  Positive 
values of IRes indicate that the CFTRinh-172-inhibited current has not decreased below the value 
of basal current prior to F508del-CFTR stimulation with forskolin.  Negative values of IRes 
indicate that the CFTRinh-172-inhibited current has decreased below the value of basal current 
prior to F508del-CFTR stimulation with forskolin.  In B – G, data are means ± SEM (C18, n = 
6; CFFT-004, n = 6, except t = 4 h, where n = 5); *, p < 0.05 vs. C18 control, unpaired t-test; †, 
p < 0.05 vs. control at time 0 h, one-way ANOVA with Dunnett’s post-test. 
 
Figure 6: Revertant mutations modify F508del-CFTR channel gating  (A) Representative 
single-channel recordings of the indicated CFTR constructs in excised inside-out membrane 
patches from BHK cells.  ATP (1 mM) and PKA (75 nM) were continuously present in the 
intracellular solution.  Dotted lines indicate the closed channel state and downward deflections 
correspond to channel openings.  (B – D) Open probability (Po), mean burst duration (MBD) 
and interburst interval (IBI) for the indicated CFTR constructs.  Data are means ± SEM (WT, 
n = 5; F508del, n = 18; F508del-G550E, Po, n = 7, MBD and IBI, n = 4; F508del-R1070W, Po, 
n = 5, MBD and IBI, n = 4; F508del-G550E-R1070W, Po, n = 6, MBD and IBI, n = 4); *, p < 
0.05 vs. WT-CFTR; †, p < 0.05 vs. F508del-CFTR.  In B – D, the wild-type and F508del-CFTR 
data are the same as Figure 3.  Other details as in Figure 3. 
 
Figure 7: Revertant mutations modify the action of CFFT-004 on F508del-CFTR  (A – C) 
Representative single-channel recordings of the indicated CFTR constructs in excised inside-
out membrane patches from BHK cells treated with CFFT-004 as a corrector or a dual-acting 
small-molecule in the same membrane patch.  ATP (1 mM) and PKA (75 nM) were 
continuously present in the intracellular solution.  Dotted lines indicate the closed channel state 
and downward deflections correspond to channel openings.  Note the change in scale bars 
between panels A and B and panel C.  For CFFT-004 correction (CF4 cor), BHK cells were 
incubated with CFFT-004 (5 M) for 24 h at 37 °C.  Prior to commencing channel recordings, 
cells were thoroughly washed to remove any residual CFFT-004 from the extracellular solution; 
the maximum period cells were left in drug-free solution before study did not exceed 30 minutes.  
For CFFT-004 dual-action (cor-pot), after recording CFFT-004 rescued F508del-CFTR channel 
activity, CFFT-004 (5 M) was added to the intracellular solution in the continuous presence 
of ATP (1 mM) and PKA (75 nM) to test its action as a CFTR potentiator.  (D – F) Open 
probability (Po) data for F508del-G550E, F508del-R1070W and F508del-G550E-R1070W 
(F508del-GE-RW) using the indicated experimental conditions (CFFT-004 correction, CF4 cor; 
42 
 
CFFT-004 potentiation, CF4 pot; CFFT-004 dual-action, CF4 cor-pot); only the key for 
F508del-G550E is shown.  Data are means ± SEM (WT, n = 5; F508del 27 °C rescue, n = 18; 
F508del-G550E, control and CF4 pot, n = 7; CF4 cor and CF4 cor-pot, n = 5; F508del-R1070W, 
control and CF4 pot, n = 5; CF4 cor and CF4 cor-pot, n = 4; F508del-G550E-R1070W, control 
and CF4 pot, n = 6, CF4 cor and CF4 cor-pot, n = 5); *, p < 0.05 vs. WT-CFTR; †, p < 0.05 vs. 
F508del-CFTR.  In D – F, the wild-type, F508del-CFTR and F508del-CFTR revertant control 
data are the same as Figures 3 and 5.  Other details as in Figure 3. 
 
Figure 8: CFFT-004 fails to rescue the CF mutant A561E-CFTR  (A – D) Representative 
single-channel records of A561E-CFTR in excised inside-out membrane patches from BHK 
cells under the indicated experimental conditions.  In A, cells were incubated at 37 °C, but not 
treated with small molecules, whereas in B and C, CFFT-004 (5 M) and C18 (5 M) were 
tested as correctors (cor) by incubation with cells for 24 h at 37 °C.  Prior to commencing 
channel recordings, cells incubated with CFFT-004 and C18 were thoroughly washed to remove 
any residual small molecules from the extracellular solution.  In D, A561E-CFTR was rescued 
at 27 °C before CFFT-004 (CF4; 5 M) and ivacaftor (VX-770 [VX]; 1 M) were tested as 
potentiators (pot) in different membrane patches.  ATP (1 mM) and PKA (75 nM) were 
continuously present in the intracellular solution.  Dotted lines indicate the closed channel state 
and downward deflections correspond to channel openings.  (E and F) Open probability (Po) 
data for indicated CFTR constructs and experimental conditions; E, CFTR correction and F, 
CFTR potentiation.  Data are means ± SEM (WT, n = 5; F508del 37 °C control, n = 15; F508del 
CFFT-004 correction, n = 6; F508del C18 correction, n = 6; A561E 37 °C control, n = 15; 
A561E CFFT-004 correction, n = 3; A561E C18 correction, n = 9; F508del 27 °C control, n = 
5; F508del CFFT-004 potentiation, n = 5; F508del VX-770 potentiation, n = 3; A561E 27 °C 
control, n = 5; A561E CFFT-004 potentiation, n = 5; A561E VX-770 potentiation, n = 3); *, p 
< 0.05 vs. WT-CFTR; †, p < 0.05 vs. F508del or A561E 27 °C control.  In E and F, the wild-
type and F508del-CFTR data are the same as Figure 3.  Other details as in Figure 3. 
 
Figure 9: CFFT-004 rescues F508del-CFTR function in primary cultures of hBE cells  (A) 
Equivalent current (Ieq) recordings from hBE cells homozygous for the F508del-CFTR 
mutation acquired at 37 °C to test the action of CFFT-004 as a corrector and dual-acting small 
molecule are shown.  Prior to commencing the recordings, hBE cells were treated for 24 h at 
37 °C with the vehicle DMSO (0.1% v v-1) (black trace), CFFT-004 (10 M) (pink trace) or 
43 
 
lumacaftor (VX-809; 3 M) (red trace).  During the indicated periods, benzamil (Bzm; 6 M) 
and CFFT-004 (CF4; 10 M) were added to the solution bathing the apical membrane, whereas 
forskolin (Fsk; 10 M) and CFTRinh-172 (I172; 20 M) were added to the solutions bathing 
both the apical and basolateral membranes.  Data are means ± SD (n = 4).  (B) Isc recordings 
from hBE cells homozygous for the F508del-CFTR mutation acquired at 37 °C to test the action 
of CFFT-004 as a potentiator are shown.  Prior to commencing the recordings, hBE cells were 
treated with lumacaftor (3 M) for 24 h at 37 °C.  During the indicated periods, benzamil (Bzm; 
6 M) and CFFT-004 (10 M), ivacaftor (1 M) or the vehicle DMSO (0.1% v v-1) were added 
to the solution bathing the apical membrane (Cmpd), whereas forskolin (Fsk; 10 M), genistein 
(Gen; 20 M) and CFTRinh-172 (I172; 20 M) were added to the solutions bathing both the 
apical and basolateral membranes.  Data are means ± SD (n = 3).  Other details as in Figure 1. 
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Table of Links 
TARGETS LIGANDS 
Ion channel 
Cystic fibrosis transmembrane conductance 
regulator, CFTR 
Forskolin 
Genistein 
Ivacaftor, VX-770 
Lumacaftor, VX-809 
 
This Table lists the protein target and ligands in this article which are hyperlinked to 
corresponding entries in http://www.guidetopharmacology.org, the common portal for data 
from the IUPHAR/BPS Guide to PHARMACOLOGY in 2016 (Southan et al., 2016) and the 
Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015). 
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Partial rescue of F508del-CFTR channel gating with modest improvement of protein 
processing, but not stability by a dual-acting small molecule 
 
Jia Liu, Hermann Bihler, Carlos M. Farinha, Nikhil T. Awatade, Ana M. Romão, Dayna 
Mercadante, Yi Cheng, Isaac Musisi, Walailak Jantarajit, Yiting Wang, Zhiwei Cai, 
Margarida D. Amaral, Martin Mense and David N. Sheppard 
 
SUPPLEMENTAL INFORMATION 
 Here, we provide further information to support our conclusion that CFFT-004 is a dual-
acting small molecule that restores function to F508del-CFTR, the most common cystic fibrosis 
mutation. 
 
 Figure S1 demonstrates that CFFT-004 potentiates the single-channel activity of low 
temperature-rescued F508del-CFTR. 
 
 Figure S2 displays CFTR-mediated transepithelial Cl- currents from CFFT-004- and 
C18-corrected F508del-CFTR-expressing FRT epithelia treated with cycloheximide used to 
investigate the plasma membrane stability of F508del-CFTR. 
 
 Figure S3 reveals that revertant mutations stabilize the single-channel activity of 
F508del-CFTR in excised membrane patches. 
 
 Figure S4 demonstrates that CFFT-004 rescues mutant CFTR Cl- channels in epithelia 
from hBE cells expressing F508del-CFTR, but not those expressing A561E-CFTR. 
 
 Figure S5 shows that CFFT-004 fails to rescue the single-channel activity of murine 
F508del-CFTR. 
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SUPPLEMENTAL METHODS 
Ussing chamber studies of human bronchial epithelia (open-circuit measurements) 
For open-circuit measurements, human bronchial epithelial (hBE) cells were seeded at 
approximately 350,000 cells/ml onto Costar Transwell® permeable supports of pore size 0.4 
µm (Snapwell, Corning-Costar®, Tewksbury, MA, USA) and area 1.13 cm2.  Transepithelial 
resistance (Rt) of hBE cell epithelia was measured with a chopstick electrode (STX2 from 
WPI®, Berlin, Germany) and electrophysiological analyses were performed on epithelia with 
Rt values above 1000-1200 Ω cm2 after 18-24 days of ALI culture.  After mounting epithelia of 
hBE cells in Ussing chambers, they were continuously perfused with a Ringer’s solution 
containing (in mM): 145 NaCl, 1.6 K2HPO4, 0.4 KH2PO4, 1 MgCl2, 1.3 Ca gluconate and 5 
glucose, pH 7.4.  Following a 20-minute stabilization period, amiloride (Amil; 20 µM) was 
added to the luminal side to block epithelial Na+ channel-mediated currents before the cAMP 
agonist forskolin (Fsk; 2 µM), the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine 
(IBMX; 100 µM), CFFT-004 (CF4; 1-30 µM), the CFTR potentiator genistein (Gen; 50 µM) 
and the CFTR inhibitor CFTRinh-172 (I172; 10 µM) were added sequentially.  Values of 
transepithelial voltage (Vt) were referenced to the luminal epithelial surface and Rt was 
determined by applying 1 s current pulses of 0.5 µA (5 s-period).  Equivalent current (Ieq) was 
calculated according to Ohm’s law from Vt and Rt values (Ieq = Vt/Rt), with appropriate 
correction for fluid resistance. 
 
SUPPLEMENTAL RESULTS 
CFFT-004 rescues native F508del-CFTR, but not A561E-CFTR Cl- channels 
 To explore further the effects of CFFT-004 on the CF mutation A561E-CFTR, we used 
hBE cells from CF patients homozygous for the A561E mutation.  As a control, we studied hBE 
cells from CF patients homozygous for F508del.  To evaluate the rescue of mutant Cl- channels 
in hBE cell epithelia, we measured equivalent current (Ieq) as described previously (Awatade et 
al., 2015).  Figure S4A and B shows representative time courses of transepithelial voltage (Vt) 
(used to calculate Ieq) for epithelia of F508del- and A561E-CFTR expressing hBE cells, while 
Figure S4C and D report mean values of transepithelial resistance (Rt) and forskolin-stimulated 
Ieq.  Pre-treatment of hBE cell epithelia with CFFT-004 (5 M) was without effect on Rt, but 
elicited a forskolin-stimulated Ieq in epithelia from F508del-CFTR expressing hBE cells, but 
not epithelia from A561E-CFTR expressing hBE cells (Figure S4).  Similarly, acute addition 
of CFFT-004 (1 – 30 M) and genistein (50 M) increased Vt in epithelia of F508del-, but not 
A561E-CFTR expressing hBE cells (Figure S4A and B).  Thus, CFFT-004 corrects and 
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potentiates native F508del-CFTR Cl- channels, but not those of A561E-CFTR consist with data 
from recombinant cells. 
 
CFFT-004 fails to rescue F508del murine CFTR 
 To investigate further the specificity of CFFT-004, we used F508del murine CFTR.  
Murine CFTR forms Cl- channels regulated by PKA-dependent phosphorylation and cycles of 
ATP binding and hydrolysis (Lansdell et al., 1998a; Scott-Ward et al., 2007).  However, the 
gating pattern of murine CFTR is characterized by prolonged openings to a low-conductance 
(10% of the full-open state) sub-conductance state and brief sojourns to the full-open state 
(Lansdell et al., 1998b; Scott-Ward et al., 2007).  In contrast to the impact of the F508del 
mutation on human CFTR (Cai et al., 2011), the gating behaviour of F508del murine CFTR is 
similar to that of wild-type murine CFTR (SJ Bose, T Liu, Z Cai, HR de Jonge and DN 
Sheppard, unpublished observation).  Figure S5A and C demonstrates that when tested as a 
CFTR potentiator, CFFT-004 (5 M) was without effect on the Po of the full-open state of 
F508del murine CFTR.  When CFFT-004 (5 M) was tested as a CFTR corrector, F508del 
murine CFTR Cl- channels were observed in excised membrane patches from CHO cells 
following PKA-dependent phosphorylation and their Po was comparable to that of low 
temperature-rescued F508del murine CFTR (Figure S5).  However, in contrast to the action of 
CFFT-004 (5 M) on F508del human CFTR, acute addition of CFFT-004 (5 M) to the 
intracellular solution following correction with CFFT-004 (5 M) did not increase the Po of the 
full-open state of F508del murine CFTR (Figure S5B and D).  Thus, CFFT-004 has independent 
corrector and potentiator activities on F508del human CFTR, but not F508del murine CFTR. 
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SUPPLEMENTAL FIGURE LEGENDS 
Figure S1: Potentiation of wild-type and F508del-CFTR by CFFT-004  (A and B) 
Representative single-channel recordings of wild-type and F508del-CFTR in excised inside-
out membrane patches from BHK cells in the absence and presence of CFFT-004 (CF4; 5 M) 
in the intracellular solution.  ATP (1 mM) and PKA (75 nM) were continuously present in the 
intracellular solution; CFFT-004 (5 M) was acutely added to the intracellular solution to 
potentiate channel gating.  Dotted lines indicate the closed channel state and downward 
deflections correspond to channel openings.  (C – E) Open probability (Po), mean burst duration 
(MBD) and interburst interval (IBI) of wild-type and F508del-CFTR in the absence and 
presence of CFFT-004 (5 M).  Data are means ± SEM (wild-type CFTR, Po, n = 4, MBD and 
IBI, n = 3; F508del-CFTR, n = 5); *, p < 0.05 vs. control.  Other details as in Figure 3. 
 
Figure S2: Deactivation of F508del-CFTR-mediated transepithelial Cl- currents after 
rescue by CFFT-004 and C18  (A – D) Representative Ussing chamber recordings of C18- 
and CFFT-004-rescued F508del-CFTR-expressing FRT epithelia.  In A and B, data are 
normalised to baseline current so that Isc represents the change in transepithelial current after 
CFTR activation by forskolin.  In C and D, Isc recordings acquired at t = 0 h are shown with 
current deflections used to measure Rt.  Fifteen minutes before t = 0 h, F508del-CFTR-
expressing FRT epithelia were treated with cycloheximide (50 g ml-1), added to both the apical 
and basolateral solutions.  At the indicated times, FRT epithelia were mounted in Ussing 
chambers and CFTR Cl- currents activated with forskolin (Fsk; 10 M), potentiated with 
ivacaftor (VX; 1 M) and inhibited with CFTRinh-172 (I172; 10 M); continuous lines indicate 
the presence of different compounds in the apical solution; cycloheximide (50 g/ml) was 
present in the apical and basolateral solutions during Isc recordings.  (E) Representative Ussing 
chamber recordings of F508del-CFTR to define the inhibited current (IInh) and the residual 
current (IRes) after CFTRinh-172 treatment.  (F) Magnitude of CFTRinh-172 (10 M) inhibited 
CFTR-mediated Isc for C18- and CFFT-004-rescued F508del-CFTR after cycloheximide, 
forskolin and ivacaftor treatments.  Data are means ± SEM (C18, n = 6; CFFT-004, n = 6, except 
t = 4 h, where n = 5; C18); †, p < 0.05 vs. control at time 0 h, one-way ANOVA with Dunnett’s 
post-test. 
 
Figure S3: Revertant mutations stabilize F508del-CFTR channel activity in excised 
inside-out membrane patches  (A – E) Time courses of Po for the indicated CFTR constructs 
6 
 
in excised inside-out membrane patches commenced once channel activation was complete and 
made in the continuous presence of ATP (1 mM) and PKA (75 nM).  With the exception of 
F508del-CFTR, all CFTR constructs were studied at 37 °C, whereas for F508del-CFTR, 
membrane patches were excised and channels activated at 27 °C before temperature was 
increased to 37 °C and Po measured.  In C – E, during the periods indicated by the bars CFFT-
004 (5 M) was present in the intracellular solution to test its action as a CFTR potentiator.  
Note the change in ordinate scale in B.  Data are means ± SEM (WT, n = 7; F508del 27 °C 
rescue, n = 10; F508del-G550E, n = 7; F508del-R1070W, n = 5; F508del-G550E-R1070W, n 
= 6).  In A and B, the wild-type and F508del-CFTR data are the same as Figure 4.  Other details 
as in Figure 3. 
 
Figure S4: CFFT-004 corrects and potentiates native F508del-CFTR Cl- channels in hBE 
cell epithelia  (A, B) Representative recordings from epithelial of CF patient derived hBE cells 
(genotype: F508del/F508del (A) and A561E/A561E (B)).  Epithelia were treated with CFFT-
004 (5 M) for 24 h at 37 °C prior to mounting in Ussing chambers and commencing Vt 
recordings.  During the periods indicated by the bars, amiloride (Amil; 10 M), forskolin (Fsk; 
2 M), IBMX (100 M), CFFT-004 (CF4; 1 – 30 M), genistein (Gen; 50 M) and CFTRinh-
172 (I172; 10 M) were added to the solution bathing the apical membrane.  Downward 
deflections of the recording correspond to increases in CFTR-mediated Vt, and hence, current.  
Note the change in scales between (A) and (B).  (C, D) Transepithelial resistance (Rt) and 
calculated change in equivalent current (Ieq) stimulated by forskolin (2 M) for epithelia of 
CF patient derived hBE cells pre-treated with CFFT-004 (5 M) or its vehicle DMSO (0.1% v 
v-1).  Data are means ± SEM (n = 3, except CFFT-004 pre-treated F508del-CFTR hBE cell 
epithelia, where n = 1). 
 
Figure S5: Effects of CFFT-004 on the single-channel activity of F508del murine CFTR  
(A and B) Representative single-channel recordings of F508del murine CFTR in excised inside-
out membrane patches from CHO cells stably expressing F508del murine CFTR.  To rescue the 
plasma membrane expression of F508del murine CFTR, CHO cells were either incubated at 27 
°C for 24 h (A) or treated with CFFT-004 (cor; 5 M) for 24 h at 37 °C (B) before CFFT-004 
(5 M) was acutely added to the intracellular solution to potentiate (pot) channel gating.  ATP 
(1 mM) and PKA (75 nM) were continuously present in the intracellular solution.  Dotted lines 
indicate the closed channel state and downward deflections correspond to channel openings.  
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Note that the sub-conductance state of murine CFTR (Lansdell et al., 1998b) is not easily 
apparent without heavy filtering of single-channel records.  (C and D) Summary Po data for the 
full-open states of F508del human and murine CFTR under the indicated experimental 
conditions.  Data are means ± SEM (F508del human CFTR (hF508del), n = 7; F508del murine 
CFTR (mF508del), n = 3, except F508del murine CFTR CFFT-004 correction and F508del 
murine CFTR CFFT-004 correction and potentiation, where data are means ± SD (n = 2); *, p 
< 0.05 vs. F508del human CFTR.  In C and D, the F508del human CFTR data are the same as 
Figure S1 and Figure 3.  Other details as in Figure 3. 
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